首页 > 最新文献

International Journal of Immunogenetics最新文献

英文 中文
Comparison of HISTO SPOT HLA AB With Cross-Match Results.
IF 2.3 4区 医学 Q3 GENETICS & HEREDITY Pub Date : 2025-03-17 DOI: 10.1111/iji.12710
Madeleine R Harris, Andrew Canterbury, Judith E Worthington, MarcusP Lowe, Marie E Hampson, Kay V Poulton

Single antigen bead assays have revolutionised the identification and definition of HLA-specific antibodies and HLA-specific antibody profiles present in patients awaiting transplantation are routinely characterised to inform organ allocation. For highly sensitised patients with a lower likelihood of finding a compatible donor, de-listing of unacceptable antigens is an option to release organ offers. In this study, 164 serum samples from 106 potential renal transplant recipients were tested using HISTO SPOT HLA AB in parallel with testing by LABScreen Single Antigen (One Lambda) and cross-matching by both CDC and flow cytometry. The results were analysed to assess the ability of HISTO SPOT HLA AB to predict a cross-match result and to understand the relative sensitivity of this test compared with other available assays. 136 samples analysed were positive for donor-specific antibodies (DSAs) using HISTO SPOT HLA AB. Of these, 17 (12.5%) were CDC positive, and 82 (60.3%) were positive by flow cytometry. A total of 28 sera which were negative for DSAs using HISTO SPOT HLA AB were negative by CDC and 25 (89.3%) were also flow cytometry cross-match negative. In this early study, HISTO SPOT HLA AB has a 100% negative predictive value for CDC and 89.3% for flow cytometry cross-matching. HISTO SPOT may therefore prove a useful additional tool to inform de-listing strategies and to facilitate transplantation in highly sensitised patients.

{"title":"Comparison of HISTO SPOT HLA AB With Cross-Match Results.","authors":"Madeleine R Harris, Andrew Canterbury, Judith E Worthington, MarcusP Lowe, Marie E Hampson, Kay V Poulton","doi":"10.1111/iji.12710","DOIUrl":"https://doi.org/10.1111/iji.12710","url":null,"abstract":"<p><p>Single antigen bead assays have revolutionised the identification and definition of HLA-specific antibodies and HLA-specific antibody profiles present in patients awaiting transplantation are routinely characterised to inform organ allocation. For highly sensitised patients with a lower likelihood of finding a compatible donor, de-listing of unacceptable antigens is an option to release organ offers. In this study, 164 serum samples from 106 potential renal transplant recipients were tested using HISTO SPOT HLA AB in parallel with testing by LABScreen Single Antigen (One Lambda) and cross-matching by both CDC and flow cytometry. The results were analysed to assess the ability of HISTO SPOT HLA AB to predict a cross-match result and to understand the relative sensitivity of this test compared with other available assays. 136 samples analysed were positive for donor-specific antibodies (DSAs) using HISTO SPOT HLA AB. Of these, 17 (12.5%) were CDC positive, and 82 (60.3%) were positive by flow cytometry. A total of 28 sera which were negative for DSAs using HISTO SPOT HLA AB were negative by CDC and 25 (89.3%) were also flow cytometry cross-match negative. In this early study, HISTO SPOT HLA AB has a 100% negative predictive value for CDC and 89.3% for flow cytometry cross-matching. HISTO SPOT may therefore prove a useful additional tool to inform de-listing strategies and to facilitate transplantation in highly sensitised patients.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of TNFRSF13B Gene Polymorphisms With SARS-CoV-2 Infection, Severity, and Humoral Immune Response in a Moroccan Population
IF 2.3 4区 医学 Q3 GENETICS & HEREDITY Pub Date : 2025-03-02 DOI: 10.1111/iji.12709
Oumaima Laazaazia, Ahd Ouladlahsen, Safaa Aqillouch, Haya Altawalah, Oumaima Bouddahab, Rachid Noureddine, Pascal Pineau, Mustapha Lkhider, Sayeh Ezzikouri

Background and Aims: Genetic factors, including polymorphisms in the TNFRSF13B gene, which regulates humoral immunity, can influence susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aims to investigate the association between two polymorphisms, rs12603708 and rs3751987, and SARS-CoV-2 susceptibility, disease severity, and humoral immune responses in a Moroccan population.

Materials and Methods: A total of 303 unvaccinated COVID-19 patients (151 severe cases and 152 asymptomatic/moderate cases) and 150 individuals from a SARS-CoV-2-negative group were included in the analysis. Genotyping was performed using TaqMan SNP assays. SARS-CoV-2 antibodies targeting the nucleocapsid protein and IgG antibodies specific to the receptor-binding domain (RBD) were quantified using chemiluminescence microparticles immunoassay. Complete blood counts and C-reactive protein levels were evaluated using an automated platform.

Results: Our analysis revealed that the A/A genotype of rs12603708 significantly increased the risk of SARS-CoV-2 infection in both codominant (p = 0.0055; OR = 3.74; adjusted p value = 0.022) and recessive (p = 0.0049; OR = 3.17; adjusted p value = 0.022) models, as well as the risk of severe disease (p = 0.014; OR = 3.43; adjusted p value = 0.049). For rs3751987, the G/G genotype was linked to higher susceptibility to infection (p = 0.0011; OR = 2.91; adjusted p value = 0.008), while the G/A genotype appeared protective (p = 0.0007; OR = 0.45; adjusted p value = 0.008). No association was found between rs3751987 and disease severity. Analysis of IgG anti-N and anti-RBD levels revealed no significant associations with either polymorphism (p > 0.05).

Conclusion: These findings highlight the role of TNFRSF13B polymorphisms in SARS-CoV-2 susceptibility and severity, while their impact on humoral immune responses appears limited.

{"title":"Association of TNFRSF13B Gene Polymorphisms With SARS-CoV-2 Infection, Severity, and Humoral Immune Response in a Moroccan Population","authors":"Oumaima Laazaazia,&nbsp;Ahd Ouladlahsen,&nbsp;Safaa Aqillouch,&nbsp;Haya Altawalah,&nbsp;Oumaima Bouddahab,&nbsp;Rachid Noureddine,&nbsp;Pascal Pineau,&nbsp;Mustapha Lkhider,&nbsp;Sayeh Ezzikouri","doi":"10.1111/iji.12709","DOIUrl":"10.1111/iji.12709","url":null,"abstract":"<div>\u0000 \u0000 <p>Background and Aims: Genetic factors, including polymorphisms in the <i>TNFRSF13B</i> gene, which regulates humoral immunity, can influence susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aims to investigate the association between two polymorphisms, rs12603708 and rs3751987, and SARS-CoV-2 susceptibility, disease severity, and humoral immune responses in a Moroccan population.</p>\u0000 <p>Materials and Methods: A total of 303 unvaccinated COVID-19 patients (151 severe cases and 152 asymptomatic/moderate cases) and 150 individuals from a SARS-CoV-2-negative group were included in the analysis. Genotyping was performed using TaqMan SNP assays. SARS-CoV-2 antibodies targeting the nucleocapsid protein and IgG antibodies specific to the receptor-binding domain (RBD) were quantified using chemiluminescence microparticles immunoassay. Complete blood counts and C-reactive protein levels were evaluated using an automated platform.</p>\u0000 <p>Results: Our analysis revealed that the A/A genotype of rs12603708 significantly increased the risk of SARS-CoV-2 infection in both codominant (<i>p</i> = 0.0055; OR = 3.74; adjusted <i>p</i> value = 0.022) and recessive (<i>p</i> = 0.0049; OR = 3.17; adjusted <i>p</i> value = 0.022) models, as well as the risk of severe disease (<i>p</i> = 0.014; OR = 3.43; adjusted <i>p</i> value = 0.049). For rs3751987, the G/G genotype was linked to higher susceptibility to infection (<i>p</i> = 0.0011; OR = 2.91; adjusted <i>p</i> value = 0.008), while the G/A genotype appeared protective (<i>p</i> = 0.0007; OR = 0.45; adjusted <i>p</i> value = 0.008). No association was found between rs3751987 and disease severity. Analysis of IgG anti-N and anti-RBD levels revealed no significant associations with either polymorphism (<i>p</i> &gt; 0.05).</p>\u0000 <p>Conclusion: These findings highlight the role of <i>TNFRSF13B</i> polymorphisms in SARS-CoV-2 susceptibility and severity, while their impact on humoral immune responses appears limited.</p>\u0000 </div>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"52 2","pages":"75-87"},"PeriodicalIF":2.3,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extended Typing of Common Erythrocyte Antigens in Tunisian Blood Donors and Its Usefulness in Transfusion Immunology
IF 2.3 4区 医学 Q3 GENETICS & HEREDITY Pub Date : 2025-02-10 DOI: 10.1111/iji.12708
Mohamed Hichem Sellami, Hamida Ferchichi, Eya Ghazouani, Noura Dellai, Yesmine Boughzala, Wafa Aissa, Manel Chaabane, Houda Kâabi, Slama Hmida

Extended RBC antigens typing is very valuable in transfusion immunology since it is highly recommended to ensure better transfusion practices and avoid transfusion-related complications and to establish registries for rare blood donors as recommended by the International Society of Blood Transfusion and World Health Organization.

A group of 236 Tunisian blood donors were genotyped for 19 common blood loci using the Sequence-specific primers polymerase chain reaction (SSP-PCR) method. The statistical analysis was done using the HaploView Software.

The study showed the dominance of the loci: RHCE*e, KEL*02, FY*02 and CO*01; and the absence of the homozygous state of the CO*02 allele. Furthermore, two complete linkage disequilibrium leading to the absence of the two alleles RHCE*C-RHCE*E (C-E) and FY*01N.01 (FY*Anull) were detected. Additionally, it appeared that approximately 91% of these blood donors are positive for the RHD gene; and all subjects who lacked the RHD exon 10 are homozygous for the RHCE*c and RHCE*e variants. The study also revealed that the RH1 negative blood cannot be universal to the Rh system because almost all RH1 negative donated blood is RH:-2,4,-3,5 (ccee), which may constitute a risk in some recipients carrying the anti-RH4 and/or anti-RH5 antibodies.

Considering that some donated RBC units may contain blood with very immunogenic phenotypes, great caution is required when transfusing some subjects, especially in emergency situations because it can be a step towards subsequent complex or multiple alloimmunization.

{"title":"Extended Typing of Common Erythrocyte Antigens in Tunisian Blood Donors and Its Usefulness in Transfusion Immunology","authors":"Mohamed Hichem Sellami,&nbsp;Hamida Ferchichi,&nbsp;Eya Ghazouani,&nbsp;Noura Dellai,&nbsp;Yesmine Boughzala,&nbsp;Wafa Aissa,&nbsp;Manel Chaabane,&nbsp;Houda Kâabi,&nbsp;Slama Hmida","doi":"10.1111/iji.12708","DOIUrl":"10.1111/iji.12708","url":null,"abstract":"<div>\u0000 \u0000 <p>Extended RBC antigens typing is very valuable in transfusion immunology since it is highly recommended to ensure better transfusion practices and avoid transfusion-related complications and to establish registries for rare blood donors as recommended by the International Society of Blood Transfusion and World Health Organization.</p>\u0000 <p>A group of 236 Tunisian blood donors were genotyped for 19 common blood loci using the Sequence-specific primers polymerase chain reaction (SSP-PCR) method. The statistical analysis was done using the HaploView Software.</p>\u0000 <p>The study showed the dominance of the loci: <i>RHCE*e</i>, <i>KEL*02</i>, <i>FY*02</i> and <i>CO*01;</i> and the absence of the homozygous state of the <i>CO*02</i> allele. Furthermore, two complete linkage disequilibrium leading to the absence of the two alleles <i>RHCE*C-RHCE*E (C-E)</i> and <i>FY*01N.01</i> (<i>FY*Anull</i>) were detected. Additionally, it appeared that approximately 91% of these blood donors are positive for the <i>RHD</i> gene; and all subjects who lacked the <i>RHD</i> exon 10 are homozygous for the <i>RHCE*c</i> and <i>RHCE*e</i> variants. The study also revealed that the RH1 negative blood cannot be universal to the Rh system because almost all RH1 negative donated blood is RH:-2,4,-3,5 (ccee), which may constitute a risk in some recipients carrying the anti-RH4 and/or anti-RH5 antibodies.</p>\u0000 <p>Considering that some donated RBC units may contain blood with very immunogenic phenotypes, great caution is required when transfusing some subjects, especially in emergency situations because it can be a step towards subsequent complex or multiple alloimmunization.</p>\u0000 </div>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"52 2","pages":"66-74"},"PeriodicalIF":2.3,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nomenclature for Factors of the HLA System, Update October, November and December 2024
IF 2.3 4区 医学 Q3 GENETICS & HEREDITY Pub Date : 2025-01-28 DOI: 10.1111/iji.12707
Steven G. E. Marsh

The following sequences have been submitted to the Nomenclature Committee since the July, August and September 2024 nomenclature update (Marsh, 2024) and, following agreed policy, have been assigned official allele designations (Marsh et al. 2010). Full details of all sequences will be published in a forthcoming report.

Below are listed the newly assigned sequences (Table 1) and confirmations of previously reported sequences (Table 2). The accession number of each sequence is given, and these can be used to retrieve the sequence files from the EMBL, GenBank or DDBJ data libraries. Although accession numbers have been assigned by the data libraries and most sequences are already available, there is still the possibility that an author may not yet have allowed the sequence to be released; in such a case, you will have to contact the submitting author directly. Additional information pertaining to new sequences is often included in the publications describing these alleles; a listing of recent publications that describe new HLA sequences is given in Table 3.

The DRB1*15:13 allele has had a Q suffix added in December 2024, now making it DRB1*15:13Q, as it was recognised in having the same amino acid deletion as had previously been described in the DRB1*11:272Q allele. The C*04:09N allele has had its suffix changed from N to L in December 2024 and is now designated C*04:09L based on information published recently indicating that this allele showed detectable levels of expression (Welters et al. 2024). A further 6 alleles, MICA*023, MICA*026, MICA*036, MICB*005:04, MICB*005:02:02 and MICB*002:01:34 were all deleted in October 2024 following the resequencing of the original material in which these alleles were first described.

All new and confirmatory sequences should now be submitted directly to the WHO Nomenclature Committee for Factors of the HLA System via the IPD-IMGT/HLA Database using the sequence submission tool provided (Barker et al. 2023; Robinson, Barker, and Marsh 2024). The IPD-IMGT/HLA Database may be accessed via the World Wide Web at: www.ebi.ac.uk/ipd/imgt/hla

The author declares no conflicts of interest.

{"title":"Nomenclature for Factors of the HLA System, Update October, November and December 2024","authors":"Steven G. E. Marsh","doi":"10.1111/iji.12707","DOIUrl":"10.1111/iji.12707","url":null,"abstract":"<p>The following sequences have been submitted to the Nomenclature Committee since the July, August and September 2024 nomenclature update (Marsh, <span>2024</span>) and, following agreed policy, have been assigned official allele designations (Marsh et al. <span>2010</span>). Full details of all sequences will be published in a forthcoming report.</p><p>Below are listed the newly assigned sequences (Table 1) and confirmations of previously reported sequences (Table 2). The accession number of each sequence is given, and these can be used to retrieve the sequence files from the EMBL, GenBank or DDBJ data libraries. Although accession numbers have been assigned by the data libraries and most sequences are already available, there is still the possibility that an author may not yet have allowed the sequence to be released; in such a case, you will have to contact the submitting author directly. Additional information pertaining to new sequences is often included in the publications describing these alleles; a listing of recent publications that describe new HLA sequences is given in Table 3.</p><p>The DRB1*15:13 allele has had a Q suffix added in December 2024, now making it DRB1*15:13Q, as it was recognised in having the same amino acid deletion as had previously been described in the DRB1*11:272Q allele. The C*04:09N allele has had its suffix changed from N to L in December 2024 and is now designated C*04:09L based on information published recently indicating that this allele showed detectable levels of expression (Welters et al. <span>2024</span>). A further 6 alleles, MICA*023, MICA*026, MICA*036, MICB*005:04, MICB*005:02:02 and MICB*002:01:34 were all deleted in October 2024 following the resequencing of the original material in which these alleles were first described.</p><p>All new and confirmatory sequences should now be submitted directly to the WHO Nomenclature Committee for Factors of the HLA System via the IPD-IMGT/HLA Database using the sequence submission tool provided (Barker et al. <span>2023</span>; Robinson, Barker, and Marsh <span>2024</span>). The IPD-IMGT/HLA Database may be accessed via the World Wide Web at: www.ebi.ac.uk/ipd/imgt/hla</p><p>The author declares no conflicts of interest.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"52 2","pages":"88-123"},"PeriodicalIF":2.3,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iji.12707","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of HLA-B Leader (−21M/T) Dimorphism With Bw4/Bw6 Epitopes on Graft Versus Host Disease After Allogenic Haematopoietic Stem Cell Transplantation in North Indians
IF 2.3 4区 医学 Q3 GENETICS & HEREDITY Pub Date : 2025-01-26 DOI: 10.1111/iji.12706
Disha Agarwal, Gaurav Sharma, Alka Khadwal, Pankaj Malhotra

High degree of variability in human leukocyte antigens (HLAs) system restricts availability of histocompatible HLA-matched-related donors, thus increasing reliance on worldwide bone marrow registries network. Nevertheless, due to limited coverage/accessibility/affordability of some ethnicities in these registries, haploidentical haematopoietic stem cell transplantation (HSCT) emerged as an alternative option, though with allorecognition-mediated graft versus host disease (GvHD) (>40% cases). A dimorphism [−21 methionine (M) or threonine (T)] in HLA-B leader peptide (exon 1) which differentially influences its HLA-E binding, plausibly regulates natural killer cell functionality, affecting GvHD vulnerability and clinically in practice for donor selection. Here, we analysed population-specific influence of this functionally relevant dimorphism on post HSCT GvHD occurrence and clinical utility (if any) towards defining donor permissibility. High resolution HLA-B genotyping data were analysed in 178 study participants, including 89 HSCT patient–donor pairs, for the frequency distribution of −21 leader dimorphism. Distribution of HLA-Bw4/Bw6 was deduced with killer cell immunoglobulin receptor ligand calculator tool in IPD-IMGT/HLA database. Though −21T (∼85%) was over represented in the study participants, no significant influence is observed for this variant between HLA-identical v/s haplo HSCT either with or without GvHD, at allelic and genotypic levels as well as in BLEAT (HLA-B Leader Assessment Tool)-based donor–recipient matching. Stratified analysis of −21 M/T into Bw4/Bw6 groups revealed a higher frequency of −21T + Bw4 in GvHD (+) group compared to GvHD (−) (p < 0.05), plausibly linking this haplotype with occurrence of GvHD post HSCT and importance of HLA class I-mediated NK cell functionality in GvHD.

{"title":"Influence of HLA-B Leader (−21M/T) Dimorphism With Bw4/Bw6 Epitopes on Graft Versus Host Disease After Allogenic Haematopoietic Stem Cell Transplantation in North Indians","authors":"Disha Agarwal,&nbsp;Gaurav Sharma,&nbsp;Alka Khadwal,&nbsp;Pankaj Malhotra","doi":"10.1111/iji.12706","DOIUrl":"10.1111/iji.12706","url":null,"abstract":"<div>\u0000 \u0000 <p>High degree of variability in human leukocyte antigens (HLAs) system restricts availability of histocompatible HLA-matched-related donors, thus increasing reliance on worldwide bone marrow registries network. Nevertheless, due to limited coverage/accessibility/affordability of some ethnicities in these registries, haploidentical haematopoietic stem cell transplantation (HSCT) emerged as an alternative option, though with allorecognition-mediated graft versus host disease (GvHD) (&gt;40% cases). A dimorphism [−21 methionine (M) or threonine (T)] in HLA-B leader peptide (exon 1) which differentially influences its HLA-E binding, plausibly regulates natural killer cell functionality, affecting GvHD vulnerability and clinically in practice for donor selection. Here, we analysed population-specific influence of this functionally relevant dimorphism on post HSCT GvHD occurrence and clinical utility (if any) towards defining donor permissibility. High resolution HLA-B genotyping data were analysed in 178 study participants, including 89 HSCT patient–donor pairs, for the frequency distribution of −21 leader dimorphism. Distribution of HLA-Bw4/Bw6 was deduced with killer cell immunoglobulin receptor ligand calculator tool in IPD-IMGT/HLA database. Though −21T (∼85%) was over represented in the study participants, no significant influence is observed for this variant between HLA-identical v/s haplo HSCT either with or without GvHD, at allelic and genotypic levels as well as in BLEAT (HLA-B Leader Assessment Tool)-based donor–recipient matching. Stratified analysis of −21 M/T into Bw4/Bw6 groups revealed a higher frequency of −21T + Bw4 in GvHD (+) group compared to GvHD (−) (<i>p</i> &lt; 0.05), plausibly linking this haplotype with occurrence of GvHD post HSCT and importance of HLA class I-mediated NK cell functionality in GvHD.</p>\u0000 </div>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"52 2","pages":"57-65"},"PeriodicalIF":2.3,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Replication Study and Meta-Analysis of the Contribution of Seven Genetic Polymorphisms in Immune-Related Genes to the Risk of Gastric and Colorectal Cancers 7种免疫相关基因多态性对胃癌和结直肠癌风险贡献的复制研究和荟萃分析。
IF 2.3 4区 医学 Q3 GENETICS & HEREDITY Pub Date : 2025-01-12 DOI: 10.1111/iji.12705
Weiguang Zhou, Siqi Yuan, Wenqiang Kang, Xiangyuan Deng, Hang Zhou, Jiangyi Ruan, Xianhong Feng, Meifang Qi, Bifeng Chen

Recently, it has been realized that immune processes participate in the pathogenesis of human cancers. A large number of genetic polymorphisms in immune-related genes have been extensively examined for their roles in the susceptibility of gastric cancer (GC) and colorectal cancer (CRC), including IL4 gene rs2070874, IL4RA gene rs1801275, IL18 gene rs187238, IL18RAP gene rs917997, IL17A gene rs8193036, IL23R gene rs1884444 and IL23R gene rs10889677. However, there is no consistent conclusion, which calls for further research. In this case–control study, these 7 genetic polymorphisms were genotyped by Sanger sequencing in a total of 1247 patients with cancer (GC/CRC: 460/787) and 800 healthy individuals. A total of 31 previous studies and our present study were included in this meta-analysis. The case–control study revealed that in Hubei Chinese population, rs2070874, rs187238 and rs10889677 were significantly associated with CRC risk, whereas only rs917997 was significantly associated with GC risk. The meta-analysis showed that rs2070874, rs917997, rs8193036 and rs1884444 were significantly associated with GC risk in Chinese population, whereas rs2070874 in total population, rs1801275 in Asian population and rs187238 in Chinese population were significantly associated with CRC risk. IL4 gene rs2070874, IL18RAP gene rs917997, IL17A gene rs8193036 and IL23R gene rs1884444 may serve as the susceptible factors for GC carcinogenesis in Chinese population. IL4 gene rs2070874 in total population, IL4RA gene rs1801275 in Asian population and IL18 gene rs187238 in Chinese population may be genetic biomarkers for CRC susceptibility.

最近,人们认识到免疫过程参与了人类癌症的发病机制。大量免疫相关基因的遗传多态性已被广泛研究其在胃癌(GC)和结直肠癌(CRC)易感性中的作用,包括IL4基因rs2070874、IL4RA基因rs1801275、IL18基因rs187238、IL18RAP基因rs917997、IL17A基因rs8193036、IL23R基因rs1884444和IL23R基因rs10889677。然而,没有一致的结论,这需要进一步的研究。在本病例对照研究中,通过Sanger测序对1247例癌症患者(GC/CRC: 460/787)和800例健康个体进行了这7种遗传多态性的基因分型。本荟萃分析共纳入了31项既往研究和本研究。病例对照研究显示,在湖北省人群中,rs2070874、rs187238和rs10889677与CRC风险显著相关,而只有rs917997与GC风险显著相关。荟萃分析显示,rs2070874、rs917997、rs8193036和rs1884444与中国人群的CRC风险显著相关,而rs2070874在总人口中、rs1801275在亚洲人群中和rs187238在中国人群中与CRC风险显著相关。IL4基因rs2070874、IL18RAP基因rs917997、IL17A基因rs8193036和IL23R基因rs1884444可能是中国人群胃癌发生的易感因素。总体人群中IL4基因rs2070874、亚洲人群中IL4RA基因rs1801275、中国人群中IL18基因rs187238可能是结直肠癌易感性的遗传生物标志物。
{"title":"Replication Study and Meta-Analysis of the Contribution of Seven Genetic Polymorphisms in Immune-Related Genes to the Risk of Gastric and Colorectal Cancers","authors":"Weiguang Zhou,&nbsp;Siqi Yuan,&nbsp;Wenqiang Kang,&nbsp;Xiangyuan Deng,&nbsp;Hang Zhou,&nbsp;Jiangyi Ruan,&nbsp;Xianhong Feng,&nbsp;Meifang Qi,&nbsp;Bifeng Chen","doi":"10.1111/iji.12705","DOIUrl":"10.1111/iji.12705","url":null,"abstract":"<div>\u0000 \u0000 <p>Recently, it has been realized that immune processes participate in the pathogenesis of human cancers. A large number of genetic polymorphisms in immune-related genes have been extensively examined for their roles in the susceptibility of gastric cancer (GC) and colorectal cancer (CRC), including <i>IL4</i> gene rs2070874, <i>IL4RA</i> gene rs1801275, <i>IL18</i> gene rs187238, <i>IL18RAP</i> gene rs917997, <i>IL17A</i> gene rs8193036, <i>IL23R</i> gene rs1884444 and <i>IL23R</i> gene rs10889677. However, there is no consistent conclusion, which calls for further research. In this case–control study, these 7 genetic polymorphisms were genotyped by Sanger sequencing in a total of 1247 patients with cancer (GC/CRC: 460/787) and 800 healthy individuals. A total of 31 previous studies and our present study were included in this meta-analysis. The case–control study revealed that in Hubei Chinese population, rs2070874, rs187238 and rs10889677 were significantly associated with CRC risk, whereas only rs917997 was significantly associated with GC risk. The meta-analysis showed that rs2070874, rs917997, rs8193036 and rs1884444 were significantly associated with GC risk in Chinese population, whereas rs2070874 in total population, rs1801275 in Asian population and rs187238 in Chinese population were significantly associated with CRC risk. <i>IL4</i> gene rs2070874, <i>IL18RAP</i> gene rs917997, <i>IL17A</i> gene rs8193036 and <i>IL23R</i> gene rs1884444 may serve as the susceptible factors for GC carcinogenesis in Chinese population. <i>IL4</i> gene rs2070874 in total population, <i>IL4RA</i> gene rs1801275 in Asian population and <i>IL18</i> gene rs187238 in Chinese population may be genetic biomarkers for CRC susceptibility.</p>\u0000 </div>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"52 1","pages":"39-55"},"PeriodicalIF":2.3,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of C4 Null Alleles and Persistently Low C4 in Asian Indian Patients With Systemic Lupus Erythematosus 亚洲印度系统性红斑狼疮患者C4空等位基因与持续低C4的关系
IF 2.3 4区 医学 Q3 GENETICS & HEREDITY Pub Date : 2025-01-12 DOI: 10.1111/iji.12704
Sachin R. Jeevanagi, Pankti Mehta, Rekha Aaron, Debashish Danda, Sumita Danda, Jayakanthan Kabeerdoss

The association between heterozygous C4 deficiency and systemic lupus erythematosus (SLE) is unclear. There is a lack of data in South Asian Indians on any possible association of C4A and C4B null alleles with lupus. We aimed to study the prevalence of C4A and C4B null alleles in a cohort of SLE patients with persistently low C4 levels compared to healthy controls (HC). Patients with SLE and HC were recruited for this prospective observational study. C4 (C4AQ and C4BQ) polymorphisms were tested using a touch-down polymerase chain reaction protocol. One hundred and three SLE patients and 103 HC were included in the study. Persistently low C4 levels were observed in 25 (23.6%) of SLE. The frequency of C4A and C4B null alleles was similarly distributed across SLE and HC (4% and 3.8%, respectively). Univariate analysis showed a low age, higher proportion of elevated dsDNA, and higher positive anti-SSA (Sjogren's syndrome-related antigen A) antibodies at presentation were associated in SLE patients with the null allele group on comparison without the null allele group. However, these associations did not persist in the multivariate analysis. In conclusion, C4 null allele frequency was similar in SLE and HC. No characteristic associations were observed in SLE with C4 null alleles was observed. Therefore, C4 null allele is an unlikely explanation for persistently low C4 in South Indian Asian patients with lupus.

杂合子C4缺乏与系统性红斑狼疮(SLE)之间的关系尚不清楚。缺乏南亚印度人C4A和C4B零等位基因与狼疮的任何可能关联的数据。我们的目的是研究与健康对照(HC)相比,C4水平持续较低的SLE患者队列中C4A和C4B空等位基因的患病率。SLE和HC患者被纳入这项前瞻性观察研究。采用触地聚合酶链反应检测C4 (C4AQ和C4BQ)多态性。103例SLE患者和103例HC患者被纳入研究。25例(23.6%)SLE患者C4水平持续低。C4A和C4B零等位基因的频率在SLE和HC中分布相似(分别为4%和3.8%)。单因素分析显示,与无空等位基因组相比,有空等位基因组的SLE患者在出现症状时年龄低、dsDNA升高比例较高、抗ssa(干燥综合征相关抗原a)抗体阳性较高。然而,这些关联在多变量分析中并未持续存在。综上所述,C4空等位基因频率在SLE和HC中相似。未观察到C4空等位基因与SLE的特征性关联。因此,C4空等位基因不太可能解释南印度亚洲狼疮患者持续低C4。
{"title":"Association of C4 Null Alleles and Persistently Low C4 in Asian Indian Patients With Systemic Lupus Erythematosus","authors":"Sachin R. Jeevanagi,&nbsp;Pankti Mehta,&nbsp;Rekha Aaron,&nbsp;Debashish Danda,&nbsp;Sumita Danda,&nbsp;Jayakanthan Kabeerdoss","doi":"10.1111/iji.12704","DOIUrl":"10.1111/iji.12704","url":null,"abstract":"<div>\u0000 \u0000 <p>The association between heterozygous C4 deficiency and systemic lupus erythematosus (SLE) is unclear. There is a lack of data in South Asian Indians on any possible association of C4A and C4B null alleles with lupus. We aimed to study the prevalence of C4A and C4B null alleles in a cohort of SLE patients with persistently low C4 levels compared to healthy controls (HC). Patients with SLE and HC were recruited for this prospective observational study. C4 (C4AQ and C4BQ) polymorphisms were tested using a touch-down polymerase chain reaction protocol. One hundred and three SLE patients and 103 HC were included in the study. Persistently low C4 levels were observed in 25 (23.6%) of SLE. The frequency of C4A and C4B null alleles was similarly distributed across SLE and HC (4% and 3.8%, respectively). Univariate analysis showed a low age, higher proportion of elevated dsDNA, and higher positive anti-SSA (Sjogren's syndrome-related antigen A) antibodies at presentation were associated in SLE patients with the null allele group on comparison without the null allele group. However, these associations did not persist in the multivariate analysis. In conclusion, C4 null allele frequency was similar in SLE and HC. No characteristic associations were observed in SLE with C4 null alleles was observed. Therefore, C4 null allele is an unlikely explanation for persistently low C4 in South Indian Asian patients with lupus.</p>\u0000 </div>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"52 1","pages":"33-38"},"PeriodicalIF":2.3,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of PADI4 Gene Polymorphisms With Susceptibility to Rheumatoid Arthritis: Evidence From 24 Case–Control Studies PADI4 基因多态性与类风湿关节炎易感性的关系:来自 24 项病例对照研究的证据。
IF 2.3 4区 医学 Q3 GENETICS & HEREDITY Pub Date : 2024-11-09 DOI: 10.1111/iji.12701
Mohammad Karimian, Fatemeh Zahra Mohammadzadeh

This study aims to investigate the association of rs11203366, rs11203367, rs874881, rs2240340 and rs1748033 polymorphisms of protein-arginine deiminase type 4 (PADI4) gene with the risk of rheumatoid arthritis (RA) through a meta-analysis that was followed with a bioinformatics approach. The data were collected from reputable articles and underwent quantitative analysis, followed by in silico analysis using some bioinformatics tools. The results showed that rs874881 polymorphism in Latino (G vs. C: OR = 1.35, 95% CI = 1.11–1.65, = 0.003; GG + CG vs. CC: OR = 2.02, 95% CI = 1.41–2.89, = 0.0001; CG vs. CC + GG: OR = 1.38, 95% CI = 1.04–1.83, = 0.027; GG vs. CC: OR = 2.09, 95% CI = 1.35–3.23, = 0.001; CG vs. CC: OR = 1.98, 95% CI = 1.36–2.87, = 0.00033) and rs1748033 in Caucasian population (T vs. C: OR = 1.25, 95% CI = 1.07–1.45, p = 0.005; TT vs. CT + CC: OR = 1.34, 95% CI = 1.09–1.64, p = 0.005, TT + CT vs. CC: OR = 1.26, 95% CI = 1.09–1.44, p = 0.001; TT vs. CC: OR = 1.59, 95% CI = 1.13–2.23, p = 0.007; CT vs. CC: OR = 1.20, 95% CI: 1.04–1.39, p = 0.015) are associated with increased risk of RA. Moreover, rs11203366 (G vs. A: OR = 1.46, 95% CI = 1.19–1.78, p = 0.0002, GG vs. AG + AA: OR = 1.42, 95% CI = 1.01–2.01, p = 0.043; GG + AG vs. AA: OR = 2.03, 95% CI = 1.45–2.86, p = 0.00004; GG vs. AA: OR = 2.29, 95% CI = 1.49–3.51, p = 0.0002; AG vs. AA: OR = 1.93, 95% CI = 1.35–2.76, p = 0.0003) and rs11203367 (T vs. C: OR = 1.50, 95% CI = 1.23–1.83, p = 0.00007; TT vs. CT + CC: OR = 1.56, 95% CI = 1.12–2.18, p = 0.009; TT + CT vs. CC: OR = 2.02, 95% CI = 1.43–2.84, p = 0.00007, TT vs. CC: OR = 2.43, 95% CI = 1.59–3.71, p = 0.0004; CT vs. CC: OR = 1.86, 95% CI = 1.30–2.68, p = 0.0007) had an impact in the Latino population. Bioinformatics tools showed the effect of these polymorphisms on gene function. These findings suggest that rs11203366, rs11203367, rs874881 and rs1748033 polymorphisms may be genetic risk factors for RA. Moreover, differences between populations suggest that ethnicity may play an important role in the effect of these polymorphisms on RA risk.

本研究旨在通过荟萃分析和生物信息学方法研究 4 型精氨酸脱氨酶(PADI4)基因 rs11203366、rs11203367、rs874881、rs2240340 和 rs1748033 多态性与类风湿性关节炎(RA)发病风险的关联。数据收集自知名文章,并进行了定量分析,随后使用一些生物信息学工具进行了硅分析。结果显示,拉丁裔的 rs874881 多态性(G vs. C:OR = 1.35,95% CI = 1.11-1.65,p = 0.003;GG + CG vs. CC:OR = 2.02,95% CI = 1.41-2.89,p = 0.0001; CG vs. CC + GG: OR = 1.38, 95% CI = 1.04-1.83, p = 0.027; GG vs. CC: OR = 2.09, 95% CI = 1.35-3.23, p = 0.001; CG vs. CC: OR = 1.98, 95% CI = 1.36-2.87, p = 0.00033)和高加索人群中的 rs1748033(T vs. C:OR = 1.25,95% CI = 1.07-1.45,p = 0.005;TT vs. CT + CC:OR = 1.34,95% CI = 1.09-1.64,p = 0.005,TT + CT vs. CC:OR = 1.26,95% CI = 1.09-1.44,p = 0.001;TT vs. CC:OR = 1.59,95% CI = 1.13-2.23,p = 0.007;CT vs. CC:OR = 1.20,95% CI:1.04-1.39,p = 0.015)与 RA 风险增加相关。此外,rs11203366(G vs. A:OR = 1.46,95% CI = 1.19-1.78,p = 0.0002;GG vs. AG + AA:OR = 1.42,95% CI = 1.01-2.01,p = 0.043;GG + AG vs. AA:OR = 2.03,95% CI = 1.45-2.86,p = 0.00004;GG vs. AA:OR = 2.29,95% CI = 1.49-3.51,p = 0.0002;AG vs. AA:OR = 1.93,95% CI = 1.35-2.76,p = 0.0003)和 rs11203367(T vs. C:OR = 1.50,95% CI = 1.45-2.86,p = 0.00004)。C:OR = 1.50,95% CI = 1.23-1.83,p = 0.00007;TT vs. CT + CC:OR = 1.56,95% CI = 1.12-2.18,p = 0.009;TT + CT vs. CC:OR = 2.02,95% CI = 1.43-2.84,p = 0.00007, TT vs. CC: OR = 2.43, 95% CI = 1.59-3.71, p = 0.0004; CT vs. CC: OR = 1.86, 95% CI = 1.30-2.68, p = 0.0007)对拉丁裔人群有影响。生物信息学工具显示了这些多态性对基因功能的影响。这些发现表明,rs11203366、rs11203367、rs874881 和 rs1748033 多态性可能是 RA 的遗传风险因素。此外,不同人群之间的差异表明,种族可能在这些多态性对 RA 风险的影响中扮演重要角色。
{"title":"Association of PADI4 Gene Polymorphisms With Susceptibility to Rheumatoid Arthritis: Evidence From 24 Case–Control Studies","authors":"Mohammad Karimian,&nbsp;Fatemeh Zahra Mohammadzadeh","doi":"10.1111/iji.12701","DOIUrl":"10.1111/iji.12701","url":null,"abstract":"<p>This study aims to investigate the association of rs11203366, rs11203367, rs874881, rs2240340 and rs1748033 polymorphisms of protein-arginine deiminase type 4 (<i>PADI4</i>) gene with the risk of rheumatoid arthritis (RA) through a meta-analysis that was followed with a bioinformatics approach. The data were collected from reputable articles and underwent quantitative analysis, followed by in silico analysis using some bioinformatics tools. The results showed that rs874881 polymorphism in Latino (G vs. C: OR = 1.35, 95% CI = 1.11–1.65, <i>p </i>= 0.003; GG + CG vs. CC: OR = 2.02, 95% CI = 1.41–2.89, <i>p </i>= 0.0001; CG vs. CC + GG: OR = 1.38, 95% CI = 1.04–1.83, <i>p </i>= 0.027; GG vs. CC: OR = 2.09, 95% CI = 1.35–3.23, <i>p </i>= 0.001; CG vs. CC: OR = 1.98, 95% CI = 1.36–2.87, <i>p </i>= 0.00033) and rs1748033 in Caucasian population (T vs. C: OR = 1.25, 95% CI = 1.07–1.45, <i>p</i> = 0.005; TT vs. CT + CC: OR = 1.34, 95% CI = 1.09–1.64, <i>p</i> = 0.005, TT + CT vs. CC: OR = 1.26, 95% CI = 1.09–1.44, <i>p</i> = 0.001; TT vs. CC: OR = 1.59, 95% CI = 1.13–2.23, <i>p</i> = 0.007; CT vs. CC: OR = 1.20, 95% CI: 1.04–1.39, <i>p</i> = 0.015) are associated with increased risk of RA. Moreover, rs11203366 (G vs. A: OR = 1.46, 95% CI = 1.19–1.78, <i>p</i> = 0.0002, GG vs. AG + AA: OR = 1.42, 95% CI = 1.01–2.01, <i>p</i> = 0.043; GG + AG vs. AA: OR = 2.03, 95% CI = 1.45–2.86, <i>p</i> = 0.00004; GG vs. AA: OR = 2.29, 95% CI = 1.49–3.51, <i>p</i> = 0.0002; AG vs. AA: OR = 1.93, 95% CI = 1.35–2.76, <i>p</i> = 0.0003) and rs11203367 (T vs. C: OR = 1.50, 95% CI = 1.23–1.83, <i>p</i> = 0.00007; TT vs. CT + CC: OR = 1.56, 95% CI = 1.12–2.18, <i>p</i> = 0.009; TT + CT vs. CC: OR = 2.02, 95% CI = 1.43–2.84, <i>p</i> = 0.00007, TT vs. CC: OR = 2.43, 95% CI = 1.59–3.71, <i>p</i> = 0.0004; CT vs. CC: OR = 1.86, 95% CI = 1.30–2.68, <i>p</i> = 0.0007) had an impact in the Latino population. Bioinformatics tools showed the effect of these polymorphisms on gene function. These findings suggest that rs11203366, rs11203367, rs874881 and rs1748033 polymorphisms may be genetic risk factors for RA. Moreover, differences between populations suggest that ethnicity may play an important role in the effect of these polymorphisms on RA risk.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"52 1","pages":"1-23"},"PeriodicalIF":2.3,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iji.12701","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations Between Interleukin-10 Polymorphisms and Susceptibility to Sjögren's Syndrome: A Meta-Analysis 白细胞介素-10 多态性与斯约格伦综合征易感性之间的关系:元分析。
IF 2.3 4区 医学 Q3 GENETICS & HEREDITY Pub Date : 2024-11-07 DOI: 10.1111/iji.12702
Young Ho Lee, Gwan Gyu Song

This study sought to investigate the association between interleukin-10 (IL10) polymorphisms and susceptibility to Sjögren's syndrome. A systematic search of the Medline, Embase and Web of Science databases was conducted to identify relevant articles from inception to April 2024. No restrictions were placed on race, ethnicity or geographic area, but only studies published in English were included. A meta-analysis was conducted to evaluate the association among the IL10-1082 G/A (rs1800896), -819 C/T (rs1800871) and -592 C/A (rs1800872) polymorphisms, as well as their haplotypes and the risk of developing Sjögren's syndrome. The included studies involved 998 Sjögren's syndrome patients and 1576 controls. Ten studies were included in the meta-analysis. Meta-analysis of the IL10-1082 G/A polymorphism revealed no significant association with Sjögren's syndrome (odds ratio [OR] = 1.115, 95% confidence interval [CI]: 0.888–1.401, p = 0.343), with stratification by ethnicity yielding consistent results for Europeans and Latin Americans. Similarly, the IL10-819 C/T polymorphism was not associated with Sjögren's syndrome in any study subjects (OR = 0.859, 95% CI: 0.648–1.138, p = 0.290). The IL10-592 C allele also exhibited no association with Sjögren's syndrome (OR = 1.131, 95% CI: 0.776–1.646, p = 0.522). However, the GCC carrier status demonstrated a significant association with Sjögren's syndrome across all study subjects (OR = 1.496, 95% CI: 1.200–1.865, p < 0.001), particularly in Europeans (OR = 1.444, 95% CI: 1.085–1.921, p = 0.012) and Latin Americans (OR = 1.324, 95% CI: 1.115–2.366, p = 0.012). A significant protective effect of the homozygous ATA/ATA haplotype on Sjögren's syndrome was found in Europeans (OR = 0.320, 95% CI: 0.121–0.846, p = 0.022).

This meta-analysis indicates a significant link between carrying the GCC haplotype of the IL10-1082 G/A, -819 C/T and -592 C/A polymorphisms and an increased susceptibility to Sjögren's syndrome. Conversely, the homozygous ATA/ATA haplotype appears to confer protection against the risk of Sjögren's syndrome, particularly in European populations.

本研究旨在探讨白细胞介素-10(IL10)多态性与斯尤格林综合征易感性之间的关系。研究人员对 Medline、Embase 和 Web of Science 数据库进行了系统检索,以确定从开始到 2024 年 4 月期间的相关文章。对种族、民族或地理区域没有限制,但只纳入了用英语发表的研究。研究人员进行了一项荟萃分析,以评估 IL10-1082 G/A (rs1800896)、-819 C/T (rs1800871) 和 -592 C/A (rs1800872) 多态性及其单倍型与罹患斯琼综合征风险之间的关联。纳入的研究涉及 998 例斯约格伦综合征患者和 1576 例对照组。有十项研究被纳入了荟萃分析。对IL10-1082 G/A多态性的荟萃分析表明,IL10-1082 G/A多态性与Sjögren综合征无明显关联(几率比[OR] = 1.115,95%置信区间[CI]:0.888-1.401):欧洲人和拉丁美洲人的种族分层结果一致。同样,在任何研究对象中,IL10-819 C/T 多态性都与斯约格伦综合征无关(OR = 0.859,95% CI:0.648-1.138,p = 0.290)。IL10-592 C 等位基因也与斯约格伦综合征无关(OR = 1.131,95% CI:0.776-1.646,p = 0.522)。然而,在所有研究对象中,GCC 携带者状态与斯约格伦综合征有显著关联(OR = 1.496,95% CI:1.200-1.865,p = 0.522)。
{"title":"Associations Between Interleukin-10 Polymorphisms and Susceptibility to Sjögren's Syndrome: A Meta-Analysis","authors":"Young Ho Lee,&nbsp;Gwan Gyu Song","doi":"10.1111/iji.12702","DOIUrl":"10.1111/iji.12702","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>This study sought to investigate the association between <i>interleukin-10</i> (<i>IL10</i>) polymorphisms and susceptibility to Sjögren's syndrome. A systematic search of the Medline, Embase and Web of Science databases was conducted to identify relevant articles from inception to April 2024. No restrictions were placed on race, ethnicity or geographic area, but only studies published in English were included. A meta-analysis was conducted to evaluate the association among the <i>IL10</i>-1082 G/A (rs1800896), -819 C/T (rs1800871) and -592 C/A (rs1800872) polymorphisms, as well as their haplotypes and the risk of developing Sjögren's syndrome. The included studies involved 998 Sjögren's syndrome patients and 1576 controls. Ten studies were included in the meta-analysis. Meta-analysis of the <i>IL10</i>-1082 G/A polymorphism revealed no significant association with Sjögren's syndrome (odds ratio [OR] = 1.115, 95% confidence interval [CI]: 0.888–1.401, <i>p</i> = 0.343), with stratification by ethnicity yielding consistent results for Europeans and Latin Americans. Similarly, the <i>IL10</i>-819 C/T polymorphism was not associated with Sjögren's syndrome in any study subjects (OR = 0.859, 95% CI: 0.648–1.138, <i>p</i> = 0.290). The <i>IL10</i>-592 C allele also exhibited no association with Sjögren's syndrome (OR = 1.131, 95% CI: 0.776–1.646, <i>p</i> = 0.522). However, the GCC carrier status demonstrated a significant association with Sjögren's syndrome across all study subjects (OR = 1.496, 95% CI: 1.200–1.865, <i>p</i> &lt; 0.001), particularly in Europeans (OR = 1.444, 95% CI: 1.085–1.921, <i>p</i> = 0.012) and Latin Americans (OR = 1.324, 95% CI: 1.115–2.366, <i>p</i> = 0.012). A significant protective effect of the homozygous ATA/ATA haplotype on Sjögren's syndrome was found in Europeans (OR = 0.320, 95% CI: 0.121–0.846, <i>p</i> = 0.022).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <p>This meta-analysis indicates a significant link between carrying the GCC haplotype of the <i>IL10</i>-1082 G/A, -819 C/T and -592 C/A polymorphisms and an increased susceptibility to Sjögren's syndrome. Conversely, the homozygous ATA/ATA haplotype appears to confer protection against the risk of Sjögren's syndrome, particularly in European populations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"52 1","pages":"24-32"},"PeriodicalIF":2.3,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iji.12702","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nomenclature for factors of the HLA system, update July, August and September 2024 HLA 系统因子命名法,2024 年 7 月、8 月和 9 月更新。
IF 2.3 4区 医学 Q3 GENETICS & HEREDITY Pub Date : 2024-10-25 DOI: 10.1111/iji.12699
Steven G. E. Marsh, for the WHO Nomenclature Committee for Factors of the HLA System

The following sequences have been submitted to the Nomenclature Committee since the April, May and June 2024 nomenclature update (Marsh, 2024) and, following agreed policy, have been assigned official allele designations (Marsh et al., 2010). Full details of all sequences will be published in a forthcoming report.

Below are listed the newly assigned sequences (Table 1) and confirmations of previously reported sequences (Table 2). The accession number of each sequence is given, and these can be used to retrieve the sequence files from the EMBL, GenBank or DDBJ data libraries. Although accession numbers have been assigned by the data libraries and most sequences are already available, there is still the possibility that an author may not yet have allowed the sequence to be released; in such a case, you will have to contact the submitting author directly. Additional information pertaining to new sequences is often included in the publications describing these alleles; a listing of recent publications that describe new HLA sequences is given in Table 3. An additional 221 alleles were recently published but have not been included in Table 3 due to space considerations (French et al., 2024; Lucas et al, 2024).

All new and confirmatory sequences should now be submitted directly to the WHO Nomenclature Committee for Factors of the HLA System via the IPD-IMGT/HLA Database using the sequence submission tool provided (Barker et al., 2023; Robinson et al., 2024). The IPD-IMGT/HLA Database may be accessed via the World Wide Web at www.ebi.ac.uk/ipd/imgt/hla.

自 2024 年 4 月、5 月和 6 月命名法更新(Marsh,2024 年)以来,以下序列已提交给命名法委员会,并按照商定的政策,被指定为正式等位基因(Marsh 等人,2010 年)。下面列出了新分配的序列(表 1)和先前报告序列的确认(表 2)。下面列出了新分配的序列(表 1)和以前报告的序列确认(表 2),并给出了每个序列的登录号,这些登录号可用于从 EMBL、GenBank 或 DDBJ 数据库中检索序列文件。虽然数据文库已经分配了登录号,而且大多数序列都已经可用,但仍有可能存在作者尚未允许发布序列的情况;在这种情况下,您必须直接联系提交序列的作者。与新序列有关的其他信息通常包含在描述这些等位基因的出版物中;表 3 列出了最近发表的描述新 HLA 序列的出版物。所有新序列和确证序列现在都应使用提供的序列提交工具(Barker 等,2023;Robinson 等,2024),通过 IPD-IMGT/HLA 数据库直接提交给世界卫生组织 HLA 系统因子命名委员会。IPD-IMGT/HLA 数据库可通过万维网访问:www.ebi.ac.uk/ipd/imgt/hla。
{"title":"Nomenclature for factors of the HLA system, update July, August and September 2024","authors":"Steven G. E. Marsh,&nbsp;for the WHO Nomenclature Committee for Factors of the HLA System","doi":"10.1111/iji.12699","DOIUrl":"10.1111/iji.12699","url":null,"abstract":"<p>The following sequences have been submitted to the Nomenclature Committee since the April, May and June 2024 nomenclature update (Marsh, <span>2024</span>) and, following agreed policy, have been assigned official allele designations (Marsh et al., <span>2010</span>). Full details of all sequences will be published in a forthcoming report.</p><p>Below are listed the newly assigned sequences (Table 1) and confirmations of previously reported sequences (Table 2). The accession number of each sequence is given, and these can be used to retrieve the sequence files from the EMBL, GenBank or DDBJ data libraries. Although accession numbers have been assigned by the data libraries and most sequences are already available, there is still the possibility that an author may not yet have allowed the sequence to be released; in such a case, you will have to contact the submitting author directly. Additional information pertaining to new sequences is often included in the publications describing these alleles; a listing of recent publications that describe new HLA sequences is given in Table 3. An additional 221 alleles were recently published but have not been included in Table 3 due to space considerations (French et al., <span>2024</span>; Lucas et al, <span>2024</span>).</p><p>All new and confirmatory sequences should now be submitted directly to the WHO Nomenclature Committee for Factors of the HLA System via the IPD-IMGT/HLA Database using the sequence submission tool provided (Barker et al., <span>2023</span>; Robinson et al., <span>2024</span>). The IPD-IMGT/HLA Database may be accessed via the World Wide Web at www.ebi.ac.uk/ipd/imgt/hla.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"51 6","pages":"397-432"},"PeriodicalIF":2.3,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iji.12699","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Immunogenetics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1